Updated:
Adragos Pharma
Adragos Pharma is a global contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, focused on the development and...
Adragos Pharma
Adragos Pharma is a global contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, focused on the development and manufacturing of pharmaceutical products. It operates an international network across Europe and Japan, with capabilities in sterile injectables and complex dosage forms. The company provides fully integrated CDMO services from development through commercial manufacturing for clients in Europe, Japan and North America.
General information
Firm type
Private Equity
Year founded
2020
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Principals
Konstantinos (Kostas) Rengis
CEO
Dr. Daniel Wigbers
CFDO
Marco Gorgas
COO
Dr. Norbert Kübler
CSO
Jeff Morrod
Chairman of the Board
Niels Erik Olsen
Vice Chairman
Stephanie Bova
Board Member
Wayne Swanton
Board Member
Moritz Hafner
Member of the Board of Directors
Aggelos Karatzas
Site Head, Athens
Ian Cooper
CEO, Halden
Mike Stradling
Global Head of Transformations
Masanori Kurogome
President and Representative Director, and Site Head, Kawagoe
Christina Doulgeri
Product Development Strategy Manager, Athens
George Georgiadis
Operational Excellence Director
Anita Kettner
Global Head of Global Supply Chain, Procurement, and ESG
Moïses Ambea Onanga
Validation Division Manager, Livron
Idir Zaïdi
Head of HSES, Maisons-Alfort
Freddy Waterloos
People Business Partner Lead Site, Maisons-Alfort
Keizo Yanagisawa
President and Representative Director, Tokyo
Bastian Baur
Global Head of Digitalization
Sector focus
Frequently asked questions
What investment strategy does Adragos Pharma follow?
Adragos Pharma lists buyout as its strategy. No further stage or sector details are provided.
Where is Adragos Pharma based?
The firm maintains its headquarters in Munich, Germany.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: